Short Interest in Pulmatrix, Inc. (NASDAQ:PULM) Decreases By 38.9%

Pulmatrix, Inc. (NASDAQ:PULM) saw a significant drop in short interest during the month of July. As of July 31st, there was short interest totaling 16,792 shares, a drop of 38.9% from the July 15th total of 27,481 shares. Currently, 0.5% of the company’s shares are short sold. Based on an average daily volume of 12,983 shares, the days-to-cover ratio is currently 1.3 days.

Pulmatrix Price Performance

PULM traded down $0.02 on Wednesday, hitting $1.53. The company had a trading volume of 5,160 shares, compared to its average volume of 42,230. Pulmatrix has a 52-week low of $1.16 and a 52-week high of $5.50. The stock has a fifty day simple moving average of $1.62 and a 200-day simple moving average of $1.74. The firm has a market capitalization of $5.58 million, a P/E ratio of -1.39 and a beta of 1.91.

Pulmatrix (NASDAQ:PULM) last posted its quarterly earnings data on Thursday, August 13th. The biotechnology company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($2.00) by $1.71.

Institutional Investors Weigh In On Pulmatrix

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. DRW Securities LLC purchased a new position in Pulmatrix during the fourth quarter valued at $46,000. Dimensional Fund Advisors LP purchased a new stake in shares of Pulmatrix in the 3rd quarter worth about $52,000. Finally, BlackRock Inc. bought a new position in shares of Pulmatrix in the 2nd quarter worth about $93,000. 11.84% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered Pulmatrix from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Pulmatrix Company Profile

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).